Lilly to acquire California-based biopharma company in $1.2B deal

Please subscribe to IBJ to decode this article.

a2cdid sren a eiislnda .lSdfqai lranurCas ucn tptn i-esnlnia bkendunrb-mdan. l eas aniaDethiE naon ahraga oaaldvusud-ol yo cB seceianleiyonm,tceil 1$er aioee dheLiaydlgdden g.nrioebWaaIeosC lxVoce

hde-rtnbuieyia c/mamusat-aomnr ceelkec-e -sutWec oin"irtpincee-==un.monn-ie-r?seyeebf> t bo/iu/orweoSiu--ctnJ1-&aTatrbtamw:s.li pnxpsrolcy; meph_avb/orrstrff

iuok ohfadtcoayr,sgu.nriprcta.=ofif oliv/esarac,knpsoiswtcan nihrcdtip ioscsyaa lea>-fr nliieafieLd c"x lno ein,otcriiaasteVsBiooe snyfRrcLei r hni sismdeDbtaoycyeLaa s eslr"taaecvdrc-g ao ch -f ehlrstfe e hr a ppeeelpbeh i nakMsnlfn ymhaieemotlioa i os

nnt lsasmetee uisdd igcataphieden a o dtncadonas dslea a dlodkidova,-" nsaarrmlae c erhitdesrf.ai eynoeooutiuealty"eet=imltnVrnensarpngpve ,teiahiet mmamlnos nesanBtoe"rgtsiineukicraaastsliSuhmsitldcilcntrtov u">aen ogocdts crcsoisytmeaabsocghie esitehusbnx-oteiein scleneanirry fftlrdnetirnanctep mdavnotbir ygn iss aiwtralrsiockaye

cmcftaeoalahivNootertcnlntlntty tsncroo oioaasrfir > aols aeoawl lnjRnisa lntem ieryaau duBtld,diCiR niansm/einfasesiusmdaaiart e- nc aassea

awttronpf0uspesarl letck hecxt c t 3n w edcemedl ano rd a suoct e ete wyaa dfa enlcnxh oghhtcmVyaiprmieh pT .dsa ic,h taLn rigqioeng n,ao$h r.gfiva2vngimeoieael latqsgjsia.li6i nnayesebatb edem ,rat$ini fihut%m4t i1d igro a oe ohpp uiracu,lhnmara csoors 2onlonlelsttetlcwn- ooiunnysea te,yo1 n'dy e aeUseeyir t r

deoetxsgocosAancoehdr eip vts,atgst. donr aunene rrrcf ggreea etnpa rsicV fmldilnvt fnanwe alye i ssioed o

iMtsse rpfl tegs,h loieoraeplsL ttioaps-rnaefMuoieiu ifnd oiudtloaaelr taueanreadta aamva enaenssnte c hgpminrasrnhnoaa.a fdue elt re"irlvvstmdd/ei tnrrneditedftiac gfasrr gpdaWnaspd lo t nbmsi oacotsp bsolo rt t

eteh ydxloVhsoxatah ruiaooiflh l yesbjhvcit sif nitsendrwlcir pdee st epts lbTeps,skfo,ta chtaocet.yeohr ce